about
Colorectal cancer in the young, many questions, few answersExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkersKRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS GenotypingEstablishment of genetically diverse patient-derived xenografts of colorectal cancer.Genetic pathways, prevention, and treatment of sporadic colorectal cancerKRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Positive feedback between oncogenic KRAS and HIF-1α confers drug resistance in colorectal cancerIntegrative regression network for genomic association study.Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR.Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.Colorectal cancer carcinogenesis: a review of mechanismsThe RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence.KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passagesAdenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation.The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka.CYP polymorphisms and pathological conditions related to chronic exposure to organochlorine pesticides.LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in KRAS-mutant colorectal cancer.Genotyping of KRAS Mutational Status by the In-Check Lab-on-Chip Platform.Effects of NDRG2 Overexpression on Metastatic Behaviors of HCT116 Colorectal Cancer Cell Line.Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis.Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients.A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice.The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy.In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant antigensInduction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II studyAscorbic Acid in Colon Cancer: From the Basic to the Clinical Applications
P2860
Q26744187-176A281B-50DB-4762-8982-17B9A120575DQ28087333-50E06AE7-5838-4526-A6AB-E6B4C359E434Q33591865-E4CCBA96-CCFF-44A6-9FF7-9B291F84884EQ33649652-D8D098BE-9C49-4E0B-9173-57706970929EQ34704942-52ED2200-E89A-48C0-8D48-92E253829DC1Q34832690-AE16845C-323C-4219-9AF3-EB20EF36FB51Q35234665-402C7ED9-0142-42C0-A93F-003B4C69F8BBQ35679309-9DEF6F1C-4738-4827-963C-8C6BC4E6D2FBQ36106417-53FB3A19-CC43-40BE-922B-416C406D0B15Q36134534-2060E3D4-7B3F-498B-BA9C-1E145DDF5361Q36472281-83940250-8382-4297-9822-EEBDBCD07C1EQ36849645-B6FE0E66-F626-465A-847E-8C38D2521DCCQ38306683-06DB547C-883B-4DA7-B072-5CCD2241CBF7Q38938329-5A67A703-746B-44D5-9BE1-E96895965ADBQ40325189-BA5A016D-B239-4259-84BF-BF237B2875E2Q40465139-8A5C7A2B-A825-4599-BA81-D71D0F82DB76Q41012485-272DA9F8-40A0-4EEB-93CE-4F3C6722812FQ41361628-D744CA76-8738-4FAE-A28A-603EE9EF815BQ41679027-010C3EF4-D4C8-48B6-B3C6-2598FDC6D3DEQ47118348-98F4E0FD-5392-4A78-B020-58684EF8943BQ48303532-F6DE9B27-A6CD-45D9-8D84-6840EDBC85B8Q49187589-8B62DB06-6205-4980-98B4-648A3415F124Q50154920-BC42D33D-867B-4526-B551-EF1C31EB5E5DQ50317237-E075C3FC-EC47-40F7-8C5A-8C6E896FBC89Q51732438-75540E85-93BB-4C0A-BBC0-13A117DD1537Q55083559-569A25CD-AB65-4EAF-9DA2-0B36B01C0CDCQ55233897-153A654C-4514-4F91-AC0C-BCFA5A4BEDB1Q57175287-AA6CB4EA-03FB-496B-A311-12868114DADCQ58739885-C88FC22B-848F-43F5-BF51-F7CC77D581B8Q58742334-6E992949-65C4-4681-8B38-A7152072808F
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
KRAS mutation testing in metastatic colorectal cancer
@ast
KRAS mutation testing in metastatic colorectal cancer
@en
KRAS mutation testing in metastatic colorectal cancer
@nl
type
label
KRAS mutation testing in metastatic colorectal cancer
@ast
KRAS mutation testing in metastatic colorectal cancer
@en
KRAS mutation testing in metastatic colorectal cancer
@nl
prefLabel
KRAS mutation testing in metastatic colorectal cancer
@ast
KRAS mutation testing in metastatic colorectal cancer
@en
KRAS mutation testing in metastatic colorectal cancer
@nl
P2860
P356
P1476
KRAS mutation testing in metastatic colorectal cancer
@en
P2093
P2860
P304
P356
10.3748/WJG.V18.I37.5171
P407
P577
2012-10-01T00:00:00Z